A critical role for Phocaeicola vulgatus in negatively impacting metformin response in diabetes
Man‐Yun Chen, Yilei Peng, Yuhui Hu, Zhiqiang Kang, Ting Chen, Yulong Zhang, Xiaoping Chen, Qing Li, Zuyi Yuan, Yue Wu, Heng Xu, Gan Zhou, Tao Liu, Honghao Zhou, Chun‐Su Yuan, Weihua Huang, Wei Zhang
Abstract
Metformin has been demonstrated to attenuate hyperglycaemia by modulating the gut microbiota. However, the mechanisms through which the microbiome mediates metformin monotherapy failure (MMF) are unclear. Herein, in a prospective clinical cohort study of newly diagnosed type 2 diabetes mellitus (T2DM) patients treated with metformin monotherapy, metagenomic sequencing of faecal samples revealed that Phocaeicola vulgatus abundance was approximately 12 times higher in nonresponders than in responders. P. vulgatus rapidly hydrolysed taurine-conjugated bile acids, leading to ceramide accumulation and reversing the improvements in glucose intolerance conferred by metformin in high-fat diet-fed mice. Interestingly, C22:0 ceramide bound to mitochondrial fission factor to induce mitochondrial fragmentation and impair hepatic oxidative phosphorylation in P. vulgatus -colonized hyperglycaemic mice, which could be exacerbated by metformin. This work suggests that metformin may be unsuitable for P. vulgatus -rich T2DM patients and that clinicians should be aware of metformin toxicity to mitochondria. Suppressing P. vulgatus growth with cefaclor or improving mitochondrial function using adenosylcobalamin may represent simple, safe, effective therapeutic strategies for addressing MMF. The commensal bacterium Phocaeicola vulgatus increased hepatic ceramide accumulation to induce mitochondrial fragmentation and impair oxidative phosphorylation, and reverse the improvements in glucose intolerance conferred by metformin.